Table 1 Characteristics of the study population

Female, No. (%)

82 (81)

165 (72)

247 (75)

0.08

Age, Median (IQR), years

38 (34–46)

40 (36–46)

39 (35–46)

0.09

BMI, Median (IQR), kg/m²

22.8 (21.5–25.3)

22.9 (20.3–27.1)

22.9 (20.5-26.6)

0.11

Nadir CD4 Median (IQR), cells/μl

164 (94–265)

186 (76–297)

185 (79–297)

0.79

Current CD4 Median (IQR), cells/μl

545 (337–679)

456 (335–630)

463 (329–640)

0.22

CrCl^d, Median (IQR), ml/min/1.73m²

99 (78–118)

96 (77–126)

95 (77–118)

0.21

CrCl < 60 ml/min/1.73 m², No (%)

5 (5)

19 (8)

24 (7)

0.28

Efavirenz-based ART, No. (%)^b

71 (70)

147 (64)

218 (66)

0.28

Duration on tenofovir, Median (IQR), months

20 (12–24)

HBsAg positive^a, No. (%)

20/56 (36)

8/101 (8)

28/157 (18)

0.0004

Proteinuria (dipstick), No. (%)

62 (61)

73 (32)

123 (37)

<0.0001

uPCR^b, Median (IQR), mg/mmol

10.8 (6.8–15.1)

5.7 (3.3–10.4)

7.7 (5.2–12.9)

<0.0001

uACR^b, Median (IQR), mg/mmol

2 (0.58–2.4)

2.1 (1.0–4.6)

2 (0.7–3.4)

0

uAPR^e, Median (IQR), mg

0.24 (0.1–0.4)

0.58 (0.4–0.6)

0.43 (0.2–0.6)

0.0006

Fractional phosphate excretion > 18 %^d, No. (%)

2/28 (7)

6/54 (11)

8/82 (10)

0.57

Fractional urate excretion > 15 %^d, No. (%)

1/28 (4)

4/54 (7)

5/82 (6)

0.49

Glycosuria (dipstick), No. (%)

24 (24)

5 (2)

29 (9)

<0.0001